免疫治疗在实体瘤中的应用现状

doi:10.11904/j.issn.1002-3070.2024.01.009

摘要/Abstract

摘要： 癌症免疫治疗具有巨大潜力,有望成为癌症治疗的主流手段。在目前的癌症免疫治疗应用中,免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)已取得显著成效。目前临床上广泛应用的ICIs包括靶向细胞毒性T淋巴细胞相关抗原4(Cytotoxic T lymphocyte-associated antigen-4,CTLA-4)、程序性死亡受体1(Programmed death-1,PD-1)及程序性死亡受体配体1(Programmed death-ligand 1,PD-L1)的抑制剂。此外,溶瘤病毒和嵌合抗原受体T细胞等新型免疫治疗也逐渐进入临床,ICIs相关的联合治疗更是显示出了独特的优势。本文将重点对ICIs、溶瘤病毒、嵌合抗原受体T细胞疗法的单独或组合形式在实体瘤中的应用现状进行综述。

关键词: 免疫治疗, 免疫检查点抑制剂, 溶瘤病毒疗法, 嵌合抗原受体T细胞疗法

Abstract: Cancer immunotherapy has great potential and is expected to become the mainstream method of cancer treatment.In the current application of cancer immunotherapy,immune checkpoint inhibitors(ICIs)have achieved remarkable results.The currently widely used ICIs in clinical practice include inhibitors targeting cytotoxic T lymphocyte-associated antigen-4(CTLA-4),programmed death-1(PD-1)and programmed death-ligand 1(PD-L1).In addition,new immunotherapies such as oncolytic viruses and chimeric antigen receptor T cells are gradually entering the clinical practice,and combination therapy related to ICIs has shown unique advantages.This article will focus on the current application status of ICIs,oncolytic viruses,and chimeric antigen receptor T cell therapies in solid tumors either their individual or combined forms.

Key words: Immunotherapy, Immune checkpoint inhibitors, Oncolytic virus therapy, Chimeric antigen receptor T cell therapy

中图分类号:

R730.3

赵璐, 张正凤, 王大臻, 杨柳, 刘泽, 娄长杰. 免疫治疗在实体瘤中的应用现状[J]. 实用肿瘤学杂志, 2024, 38(1): 55-61.

ZHAO Lu, ZHANG Zhengfeng, WANG Dazhen, YANG Liu, LIU Ze, LOU Changjie. The current application status of immunotherapy in solid tumors[J]. Journal of Practical Oncology, 2024, 38(1): 55-61.

参考文献

1 Wang SJ,Dougan SK,Dougan M.Immune mechanisms of toxicity from checkpoint inhibitors[J].Trends Cancer,2023,9(7):543-553.
2 Jiang Y,Chen M,Nie H,et al.PD-1 and PD-L1 in cancer immunotherapy:clinical implications and future considerations[J].Hum Vaccin Immunother,2019,15(5):1111-1122.
3 Linsley PS,Brady W,Grosmaire L,et al.Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation[J].J Exp Med,1991,173(3):721-730.
4 Kang SP,Gergich K,Lubiniecki GM,et al.Pembrolizumab KEYNOTE-001:an adaptive study leading to accelerated approval for two indications and a companion diagnostic[J].Ann Oncol,2017,28(6):1388-1398.
5 Raedler LA.Keytruda(pembrolizumab):First PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma[J].Am Health Drug Benefits,2015,8:96-100.
6 Burtness B,Harrington KJ,Greil R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J].Lancet,2019,394(10212):1915-1928.
7 Fuchs CS,Doi T,Jang RW,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:Phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncol,2018,4(5):e180013.
8 Marcus L,Lemery SJ,Keegan P,et al.FDA approval summary:pembrolizumab for the treatment of microsatellite instability-high solid tumors[J].Clin Cancer Res,2019,25(13):3753-3758.
9 Chung HC,Ros W,Delord JP,et al.Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer:results from the phase II KEYNOTE-158 study[J].J Clin Oncol,2019,37(17):1470-1478.
10 Borcoman E,Le Tourneau C.KEYNOTE-158 study,FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer[J].Ann Transl Med,2020,8(23):1611.
11 Vuky J,Balar AV,Castellano D,et al.Long-term outcomes in KEYNOTE052:Phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer[J].J Clin Oncol,2020,38(23):2658-2666.
12 Schmid P,Salgado R,Park YH,et al.Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk,early-stage triple-negative breast cancer:results from the phase 1b open-label,multicohort KEYNOTE -173 study[J].Ann Oncol,2020,31(5):569-581.
13 Marabelle A,Fakih M,Lopez J,et al.Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab:prospective biomarker analysis of the multicohort,open-label,phase 2 -KEYNOTE158 study[J].Lancet Oncol,2020,21(10):1353-1365.
14 O′malley DM,Bariani GM,Cassier PA,et al.Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer:results from the KEYNOTE-158 study[J].J Clin Oncol,2022,40(7):752-761.
15 Pavri SN,Clune J,Ariyan S,et al.Malignant melanoma:beyond the basics[J].Plast Reconstr Surg,2016,138(2):330-340.
16 Rizvi NA,Mazières J,Planchard D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer(CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.
17 Motzer RJ,Rini BI,Mcdermott DF,et al.Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma:extended follow-up of efficacy and safety results from a randomised,controlled,phase 3 trial[J].Lancet Oncol,2019,20(10):1370-1385.
18 Johnson DE,Burtness B,Leemans CR,et al.Head and neck squamous cell carcinoma[J].Nat Rev Dis Primers,2020,6(1):92.
19 Overman MJ,Mcdermott R,Leach JL,et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142):an open-label,multicentre,phase 2 study[J].Lancet Oncol,2017,18(9):1182-1191.
20 Tawbi HA,Schadendorf D,Lipson EJ,et al.Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma[J].N Engl J Med,2022,386(1):24-34.
21 Forde PM,Spicer J,Lu S,et al.Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J].N Engl J Med,2022,386(21):1973-1985.
22 Doki Y,Ajani JA,Kato K,et al.Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma[J].N Engl J Med,2022,386(5):449-462.
23 Migden MR,Rischin D,Schmults CD,et al.PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma[J].N Engl J Med,2018,379(4):341-351.
24 Keeping S,Xu Y,Chen CI,et al.Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma[J].Future Oncol,2021,17(5):611-627.
25 Markham A.Atezolizumab:first global approval[J].Drugs,2016,76(12):1227-1232.
26 Herbst RS,Giaccone G,De Marinis F,et al.Atezolizumab for first-line treatment of PD-L1-selected patients with nsclc[J].N Engl J Med,2020,383(14):1328-1339.
27 Mathieu L,Shah S,Pai-Scherf L,et al.FDA approval summary:atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer[J].Oncologist,2021,26(5):433-438.
28 Gutzmer R,Stroyakovskiy D,Gogas H,et al.Atezolizumab,vemurafenib,and cobimetinib as first-line treatment for unresectable advanced braf(v600)mutation-positive melanoma(imspire150):primary analysis of the randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2020,395(10240):1835-1844.
29 Finn RS,Qin S,Ikeda M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J].N Engl J Med,2020,382(20):1894-1905.
30 Syed YY.Durvalumab:First global approval[J].Drugs,2017,77(12):1369-1376.
31 Johnson ML,Cho BC,Luft A,et al.Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer:the phase III poseidon study[J].J Clin Oncol,2023,41(6):1213-1227.
32 Rimini M,Fornaro L,Lonardi S,et al.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer:an early exploratory analysis of real-world data[J].Liver Int,2023,43(8):1803-1812.
33 Walker JW,LebbéC,Grignani G,et al.Correction:efficacy and safety of avelumab treatment in patients with metastatic merkel cell carcinoma:experience from a global expanded access program[J].J Immunother Cancer,2020,8(1):e000313.
34 Apolo AB,Ellerton JA,Infante JR,et al.Avelumab as second-line therapy for metastatic,platinum-treated urothelial carcinoma in the phase Ib javelin solid tumor study:2-year updated efficacy and safety analysis[J].J Immunother Cancer,2020,8(2):e001246.
35 Callahan MK,Wolchok JD.At the bedside:CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy[J].J Leukoc Biol,2013,94(1):41-53.
36 Lisi L,Lacal PM,Martire M,et al.Clinical experience with CTLA-4 blockade for cancer immunotherapy:from the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment[J].Pharmacol Res,2022,175:105997.
37 Nikoo M,Rabiee F,Mohebbi H,et al.Nivolumab plus ipilimumab combination therapy in cancer:current evidence to date[J].Int Immunopharmacol,2023,117:109881.
38 Ribas A,Wolchok JD.Cancer immunotherapy using checkpoint blockade[J].Science,2018,359(6382):1350-1355.
39 Garassino MC,Gadgeel S,Speranza G,et al.Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer:5-year outcomes from the phase 3 KEYNOTE-189 study[J].J Clin Oncol,2023,41(11):1992-1998.
40 Negrao MV,Lam VK,Reuben A,et al.PD-L1 expression,tumor mutational burden,and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer[J].J Thorac Oncol,2019,14(6):1021-1031.
41 Mansfield AS,Ka·zarnowicz A,Karaseva N,et al.Safety and patient-reported outcomes of atezolizumab,carboplatin,and etoposide in extensive-stage small-cell lung cancer(IMpower133):A randomized phase I/III trial[J].Ann Oncol,2020,31(2):310-317.
42 Antonia SJ,Villegas A,Daniel D,et al.Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer[J].N Engl J Med,2017,377(20):1919-1929.
43 Xu Y,Li H,Fan Y.Progression patterns,treatment,and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer[J].Front Oncol,2021,11:642883.
44 Hong M,Clubb JD,Chen YY.Engineering CAR-T cells for next-generation cancer therapy[J].Cancer Cell,2020,38(4):473-488.
45 Meng Y,Deng B,Rong L,et al.Short-interval sequential CAR-T cell infusion may enhance prior CAR-T cell expansion to augment anti-lymphoma response in B-NHL[J].Front Oncol,2021,11:640166.
46 Zhang Y,Wang Y,Liu Y,et al.Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma:a single-arm,phase 1-2 trial[J].Leukemia,2022,36(1):189-196.
47 Li W,Qiu S,Chen J,et al.Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy[J].Immunity,2020,53(2):456-470.
48 Edeline J,Houot R,Marabelle A,et al.CAR-T cells and bites in solid tumors:Challenges and perspectives[J].J Hematol Oncol,2021,14(1):65.
49 Brown CE,Alizadeh D,Starr R,et al.Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J].N Engl J Med,2016,375(26):2561-2569.
50 Louis CU,Savoldo B,Dotti G,et al.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood,2011,118(23):6050-6056.
51 Van Bruggen JaC,Martens AWJ,Fraietta JA,et al.Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+)Tcells and impede CAR-T cell efficacy[J].Blood,2019,134(1):44-58.
52 Macedo N,Miller DM,Haq R,et al.Clinical landscape of oncolytic virus research in 2020[J].J Immunother Cancer,2020,8(2):e001486.
53 Xiao Y,Yu D.Tumor microenvironment as a therapeutic target in cancer[J].Pharmacol Ther,2021,221:107753.
54 Turley SJ,Cremasco V,Astarita JL.Immunological hallmarks of stromal cells in the tumour microenvironment[J].Nat Rev Immunol,2015,15(11):669-682.
55 Ma R,Li Z,Chiocca EA,et al.The emerging field of oncolytic virus-based cancer immunotherapy[J].Trends Cancer,2023,9(2):122-139.
56 Arcangeli S,Mestermann K,Weber J,et al.Overcoming key challenges in cancer immunotherapy with engineered t cells[J].Curr Opin Oncol,2020,32(5):398-407.
57 Springuel L,Lonez C,Alexandre B,et al.Chimeric antigen receptor-T cells for targeting solid tumors:Current challenges and existing strategies[J].BioDrugs,2019,33(5):515-537.
58 Zhao Z,Condomines M,Van Der Stegen SJC,et al.Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR-T cells[J].Cancer Cell,2015,28(4):415-428.
59 Pikor LA,Bell JC,Diallo JS.Oncolytic viruses:exploiting cancer′s deal with the devil[J].Trends Cancer,2015,1(4):266-277.
60 Ajina A,Maher J.Prospects for combined use of oncolytic viruses and CAR-T cells[J].J Immunother Cancer,2017,5(1):90.
61 Moon EK,Wang LS,Bekdache K,et al.Intra-tumoral delivery of cxcl11 via a vaccinia virus,but not by modified T cells,enhances the efficacy of adoptive t cell therapy and vaccines[J].Oncoimmunology,2018,7(3):e1395997.
62 Watanabe K,Luo Y,Da T,et al.Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses[J].JCI Insight,2018,3(7):e99573.
63 Topalian SL,Hodi FS,Brahmer JR,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.

[1]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[2]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[3]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.
[4]	李娟, 刘家仁. 胃癌免疫治疗的研究现状及进展[J]. 实用肿瘤学杂志, 2023, 37(4): 372-376.
[5]	龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.
[6]	李路桥, 邹征云. 恶性黑色素瘤免疫治疗超进展研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 144-148.
[7]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[8]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[9]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[10]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.
[11]	张玥, 汪越, 魏嘉. SHP2作为抗肿瘤治疗靶点的价值及其在肿瘤免疫治疗中的应用[J]. 实用肿瘤学杂志, 2022, 36(6): 513-519.
[12]	程思远, 韩子翰, 郭晓欢, 沈琳, 彭智. 肠道菌群与肿瘤免疫治疗疗效及不良反应关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 520-525.
[13]	杨磊, 张正凤, 王大榛, 娄长杰. 基于真实世界的晚期食管鳞癌一线标准化疗联合免疫检查点抑制剂对比标准化疗的回顾性对照研究[J]. 实用肿瘤学杂志, 2022, 36(6): 538-543.
[14]	李雄, 姜文凯, 郎泽昆, 芮少珍. 肿瘤相关中性粒细胞与胰腺癌关系的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 458-462.
[15]	刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.